Table 2.

Attribute Levels

Attribute	Description
Mode/Frequency of administration	Oral	Daily
		2–3 times per week
		Weekly
	Subcutaneous	2–3 times per week
		Weekly
		Fortnightly
		Monthly
	Intravenous	Weekly
		Fortnightly
		Monthly
Annual out-of-pocket costs (pounds)		0
		400
		800
		1200
		1600
Average overall survival/Remission period	1 year	3 months
		9 months
	2 years	6 months
		1 year 6 months
	3 years	9 months
		2 years 3 months
	4 years	1 year
		3 years
	5 years	1 year 3 months
		3 years 9 months
Mild-to-moderate side effects		None
		Low risk (20%) – Duration (up to 2 months)
		Low risk (20%) – Duration (longer than 2 months)
		Med risk (40%) – Duration (up to 2 months)
		Med risk (40%) – Duration (longer than 2 months)
		High risk (60%) – Duration (up to 2 months)
		High risk (60%) – Duration (longer than 2 months)
Severe side effects		None
		Low risk (5%) – Duration (up to 2 months)
		Low risk (5%) – Duration (longer than 2 months)
		High risk (10%) – Duration (up to 2 months)
		High risk (10%) – Duration (longer than 2 months)